Ioflupane (123i) Rotop (Ioflupane (123i))

Ioflupane is employed in diagnostic imaging of the dopaminergic system, particularly for conditions where dopamine transporter integrity is relevant.

• Parkinsonian syndromes: enables differentiation of Parkinson's disease from other movement disorders by visualizing dopamine transporter loss.
• Dementia with Lewy bodies: assists in confirming diagnosis through characteristic transporter binding patterns.
• Other neurodegenerative disorders affecting dopaminergic neurons: provides functional assessment of neuronal integrity for research and clinical evaluation.

• Ioflupane binds with high affinity to presynaptic dopamine transporters (DAT) in the striatum. After intravenous administration, the radiolabelled compound is taken up by dopaminergic neurons, allowing single‑photon emission computed tomography (SPECT) to visualize and quantify DAT density, which reflects neuronal integrity and helps distinguish disease states.

Ioflupane is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild to moderate discomfort after injection.
• Headache: transient, often resolves without treatment.
• Injection site pain: mild soreness at the venipuncture site.
• Dizziness: temporary light‑headedness post‑administration.
• Dry mouth: reduced salivation lasting a few hours.
• Fatigue: mild tiredness reported by some patients.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergy requiring immediate medical attention.
• Severe hypotension: marked drop in blood pressure after injection.
• Pulmonary edema: rare fluid accumulation in lungs.
• Seizures: infrequent neurologic events.
• Stevens‑Johnson syndrome: severe skin reaction.
• Radiation‑induced toxicity: unlikely but possible with repeated exposure.

Use of Ioflupane requires careful consideration of patient-specific factors and handling requirements.

• Pregnancy: safety not established; avoid unless benefits outweigh potential risks.
• Breastfeeding: unknown excretion in milk; consider discontinuation of nursing.
• Renal impairment: adjust use cautiously as clearance may be reduced.
• Concomitant dopamine‑affecting drugs: may alter imaging results; assess medication history.
• Pediatric use: only if diagnostic benefit justifies exposure.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with substances that influence dopamine transporter availability or alter SPECT imaging quality.

Major Interactions (Avoid)

• Cocaine or amphetamines: compete for DAT binding, leading to false‑negative scans.
• Methylphenidate: similar competitive inhibition at DAT.
• Bupropion: can reduce tracer uptake and affect image interpretation.

Moderate Interactions (Monitor Closely)

• MAO inhibitors: may modestly affect DAT density.
• Antipsychotics (e.g., haloperidol): alter dopaminergic signaling and could impact results.
• Antihypertensives: monitor blood pressure as injection may cause transient changes.